請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20491
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蔡幸真 | |
dc.contributor.author | Yen-Wei Chen | en |
dc.contributor.author | 陳彥瑋 | zh_TW |
dc.date.accessioned | 2021-06-08T02:50:35Z | - |
dc.date.copyright | 2017-09-13 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-08-16 | |
dc.identifier.citation | 1. Qiu J. Epigenetics: unfinished symphony. Nature 2006;441:143-5.
2. Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat Rev Genet 2016;17:487-500. 3. Robertson KD, Uzvolgyi E, Liang G, et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 1999;27:2291-8. 4. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999;99:247-57. 5. Liao J, Karnik R, Gu H, et al. Targeted disruption of DNMT1, DNMT3A and DNMT3B in human embryonic stem cells. Nature genetics 2015;47:469-78. 6. Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci U S A 2006;103:1412-7. 7. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev 2011;25:1010-22. 8. Kulis M, Esteller M. DNA methylation and cancer. Adv Genet 2010;70:27-56. 9. Russler-Germain DA, Spencer DH, Young MA, et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 2014;25:442-54. 10. Wang Z, Zang C, Rosenfeld JA, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 2008;40:897-903. 11. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011;21:381-95. 12. Jones PA, Issa J-PJ, Baylin S. Targeting the cancer epigenome for therapy. Nature reviews Genetics 2016;17:630-41. 13. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010;42:181-5. 14. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019-32. 15. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. New England Journal of Medicine 2013;369:98-. 16. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012;481:506-10. 17. Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH. Cancer Stem Cells (CSCs) and Mechanisms of Their Regulation: Implications for Cancer Therapy. Current protocols in pharmacology / editorial board, SJ Enna (editor-in-chief) [et al] 2013;0 14:Unit-14.25. 18. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-8. 19. Wang JC, Lapidot T, Cashman JD, et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 1998;91:2406-14. 20. Shlush LI, Mitchell A, Heisler L, et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature 2017;547:104-8. 21. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 1991;77:2031-6. 22. Tsai H-C, Li H, Van Neste L, et al. Transient Low Doses of DNA Demethylating Agents Exert Durable Anti-tumor Effects on Hematological and Epithelial Tumor Cells. Cancer Cell 2012;21:430-46. 23. Waddington CH. The Strategy of the Genes. London: Routledge; 1957. 24. Xie W, Schultz MD, Lister R, et al. Epigenomic Analysis of Multi-lineage Differentiation of Human Embryonic Stem Cells. Cell 2013;153:1134-48. 25. Gifford CA, Ziller MJ, Gu H, et al. Transcriptional and epigenetic dynamics during specification of human embryonic stem cells. Cell 2013;153:1149-63. 26. Hogart A, Lichtenberg J, Ajay SS, Anderson S, Margulies EH, Bodine DM. Genome-wide DNA methylation profiles in hematopoietic stem and progenitor cells reveal overrepresentation of ETS transcription factor binding sites. Genome research 2012;22:1407-18. 27. Cui K, Zang C, Roh TY, et al. Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell Stem Cell 2009;4:80-93. 28. Munoz P, Iliou MS, Esteller M. Epigenetic alterations involved in cancer stem cell reprogramming. Mol Oncol 2012;6:620-36. 29. Easwaran H, Tsai H-C, Baylin SB. Cancer epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance. Molecular cell 2014;54:716-27. 30. Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006;125:315-26. 31. Marjanovic ND, Weinberg RA, Chaffer CL. Cell plasticity and heterogeneity in cancer. Clin Chem 2013;59:168-79. 32. Chaffer CL, Brueckmann I, Scheel C, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A 2011;108:7950-5. 33. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93. 34. Cruijsen M, Lubbert M, Wijermans P, Huls G. Clinical Results of Hypomethylating Agents in AML Treatment. J Clin Med 2014;4:1-17. 35. Tsai HC, Li H, Van Neste L, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer cell 2012;21:430-46. 36. Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 1998;58:95-101. 37. Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 2002;21:5496-503. 38. Srivastava P, Paluch BE, Matsuzaki J, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget 2016;7:12840-56. 39. Wrangle J, Wang W, Koch A, et al. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget 2013;4:2067-79. 40. Chiappinelli KB, Strissel PL, Desrichard A, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell 2015;162:974-86. 41. Roulois D, Loo Yau H, Singhania R, et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell;162:961-73. 42. Shukla S, Meeran SM. Epigenetics of cancer stem cells: Pathways and therapeutics. Biochim Biophys Acta 2014;1840:3494-502. 43. Larizza L, Magnani I, Beghini A. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma 2005;46:247-55. 44. Sidney LE, Branch MJ, Dunphy SE, Dua HS, Hopkinson A. Concise Review: Evidence for CD34 as a Common Marker for Diverse Progenitors. Stem Cells (Dayton, Ohio) 2014;32:1380-9. 45. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84. 46. Sampieri K, Fodde R. Cancer stem cells and metastasis. Semin Cancer Biol 2012;22:187-93. 47. Toh TB, Lim JJ, Chow EK-H. Epigenetics in cancer stem cells. Molecular Cancer 2017;16:29. 48. Zhang C, Suo J, Katayama H, Wei Y, Garcia-Manero G, Hanash S. Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines. Clinical Proteomics 2016;13:14. 49. Abedin S, Platanias LC. PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS. Leuk Lymphoma 2017;58:764-5. 50. Riccadonna C, Yacoub Maroun C, Vuillefroy de Silly R, et al. Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing. PLoS One 2016;11:e0162105. 51. Shalon D, Smith SJ, Brown PO. A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res 1996;6:639-45. 52. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015;43:e47. 53. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature genetics 2000;25:25-9. 54. Gene Ontology Consortium: going forward. Nucleic Acids Res 2015;43:D1049-56. 55. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50. 56. Dedeurwaerder S, Defrance M, Bizet M, Calonne E, Bontempi G, Fuks F. A comprehensive overview of Infinium HumanMethylation450 data processing. Briefings in Bioinformatics 2014;15:929-41. 57. Maksimovic J, Gordon L, Oshlack A. SWAN: Subset-quantile Within Array Normalization for Illumina Infinium HumanMethylation450 BeadChips. Genome Biology 2012;13:R44. 58. Aryee MJ, Jaffe AE, Corrada-Bravo H, et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics (Oxford, England) 2014;30:1363-9. 59. Yu G, Wang LG, He QY. ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics (Oxford, England) 2015;31:2382-3. 60. Ernst J, Kheradpour P, Mikkelsen TS, et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 2011;473:43-9. 61. The Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nature genetics 2013;45:1113-20. 62. Gutierrez-Arcelus M, Lappalainen T, Montgomery SB, et al. Passive and active DNA methylation and the interplay with genetic variation in gene regulation. eLife 2013;2:e00523. 63. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological) 1995;57:289-300. 64. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Meth 2012;9:357-9. 65. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics (Oxford, England) 2009;25:2078-9. 66. Ramírez F, Dündar F, Diehl S, Grüning BA, Manke T. deepTools: a flexible platform for exploring deep-sequencing data. Nucleic Acids Research 2014;42:W187-W91. 67. Zhang Y, Liu T, Meyer CA, et al. Model-based Analysis of ChIP-Seq (MACS). Genome Biology 2008;9:R137. 68. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5. 69. Raney BJ, Dreszer TR, Barber GP, et al. Track data hubs enable visualization of user-defined genome-wide annotations on the UCSC Genome Browser. Bioinformatics 2014;30:1003-5. 70. Ihaka RG. R: A language for data analysis and graphics. J Comput Graph Stat 1996;5. 71. Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York2009. 72. Medvedeva YA, Lennartsson A, Ehsani R, et al. EpiFactors: a comprehensive database of human epigenetic factors and complexes. Database (Oxford) 2015;2015:bav067. 73. Palmer NP, Schmid PR, Berger B, Kohane IS. A gene expression profile of stem cell pluripotentiality and differentiation is conserved across diverse solid and hematopoietic cancers. Genome Biol 2012;13:R71. 74. Yang AS, Doshi KD, Choi SW, et al. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res 2006;66:5495-503. 75. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-7. 76. McGarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T, Baylin SB. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 2006;66:3541-9. 77. Brodská B, Holoubek A, Otevřelová P, Kuželová K. Combined Treatment with Low Concentrations of Decitabine and SAHA Causes Cell Death in Leukemic Cell Lines but Not in Normal Peripheral Blood Lymphocytes. BioMed Research International 2013;2013:659254. 78. Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 2014;28:1280-8. 79. Riccadonna C, Yacoub Maroun C, Vuillefroy de Silly R, et al. Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing. PLOS ONE 2016;11:e0162105. 80. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65. 81. Héninger E, Krueger TEG, Lang JM. Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents. Frontiers in Immunology 2015;6:29. 82. Karpf AR. A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics 2006;1:116-20. 83. Jaatinen T, Hemmoranta H, Hautaniemi S, et al. Global gene expression profile of human cord blood-derived CD133+ cells. Stem Cells 2006;24:631-41. 84. Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. Jama 2010;304:2706-15. 85. Eppert K, Takenaka K, Lechman ER, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011;17:1086-93. 86. Binato R, de Almeida Oliveira NC, Du Rocher B, Abdelhay E. The molecular signature of AML mesenchymal stromal cells reveals candidate genes related to the leukemogenic process. Cancer Lett 2015;369:134-43. 87. Gal H, Amariglio N, Trakhtenbrot L, et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 2006;20:2147-54. 88. Miller BG, Stamatoyannopoulos JA. Integrative Meta-Analysis of Differential Gene Expression in Acute Myeloid Leukemia. PLoS ONE 2010;5:e9466. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20491 | - |
dc.description.abstract | 表觀遺傳學是一門研究不改變DNA序列卻能夠影響基因表現,並將基因表現之變化在細胞分裂中遺傳至子細胞的學問。該門學問與胚胎幹細胞及血液幹細胞的分化息息相關。而對於具有腫瘤生成能力的癌症幹細胞,表觀遺傳學的研究仍有進步空間。因此本研究使用急性骨髓性白血病的Kasumi-1細胞株,先透過細胞表面的CD34蛋白標記,分出了可以在老鼠中引發白血病的CD34陽性細胞以及無法在老鼠中引發白血病的CD34陰性細胞亞群,接著使用地西他濱(decitabine)分別處理各細胞亞群,抑制細胞內之DNA甲基轉移脢、以促使CD34陽性血癌細胞分化、並降低其在老鼠體內形成血癌之能力, 再配合高通量分析技術,分析這些細胞全基因之轉錄體、甲基體以及組蛋白修飾情形。以期能找出表觀遺傳機轉於CD34陽性幹細胞致癌性及分化能力所扮演的角色,以及低劑量地西他濱如何透過去甲基化以外的機轉影響形成血癌的能力。我的研究發現,甲基化以及組蛋白修飾對於幹細胞特性相關基因調控扮演重要的角色,幹細胞特性基因之啟動子於CD34陽性血癌細胞中甲基化程度低及H3K27me3組蛋白修飾低,導致幹細胞特性基因高度表達。而以低劑量去甲基化藥物地西他濱處理後,除了發現基因甲基化程度整體下降以及分化相關基因表達上升之外,亦發現特定之組蛋白修飾如H3K4me3以及H3K27me3於基因啟動子處都明顯下降的現象。。除此之外,也發現decitabine處理過後再表現以及沒有再表現的基因,即使和處理前的甲基化還有組蛋白修飾相比都是明顯下降。處理前的H3K27me3仍可以提供線索告訴我們他會不會再表現。透過這個特性進一步發現被decitabine所促進的分化相關基因,都在處理前具有較高的H3K27me3以導致其在處理後的再表現。除此之外也注意到了decitabine的處理可以降低CD34陽性細胞還有陰性細胞的分化基因表現差距,以及調控這些基因的甲基化和組蛋白修飾H3K27me3差距都有下降的現象,說明了decitabine有可能降低癌症中次族群中的差異性。整體而言這份研究說明了癌症幹細胞致癌特性會受到甲基化以及組蛋白修飾影響,而經過地西他濱處理後會經過複雜的表觀遺傳學機制降低其幹細胞致癌特性。 | zh_TW |
dc.description.abstract | Epigenetics refers to study of heritable gene expression changes without changing DNA sequence. Epigenetic mechanisms play important roles in many biological processes, including embryonic and somatic stem cell differentiation. However, how epigenetic mechanisms regulate cancer-initiating capacity of cancer stem cells is still unclear. Thus, we used Kasumi-1 cells as model system, which is an acute myelogenous leukemia cell line containing leukemogenic CD34-positive (CD34pos) and non-leukemogenic CD34-negative (CD34neg) cell subpopulations. We conducted integrative bioinformatics analysis on genome-wide transcriptomes (gene expression arrays), methylation profiles (Infinium 450K arrays), and histone modifications (ChIP-seq) to investigate how cancer stemness is regulated by epigenetic mechanisms. Furthermore, we studied whether and how decitabine, a DNMT inhibitor, acts beyond DNA demethylation to diminish leukemogenicity through chromatin changes. The analyses revealed lower DNA methylation and H3K27me3 levels at the promoters of stemness-related genes in CD34pos cells, correlated with higher transcriptional activities of these genes. After decitabine treatment, a global decrement of H3K4me3 and H3K27me3 enrichments near transcription start site was noted, possibly due to loosening of chromatin configuration. In addition, genes with higher H3K27me3 promoter enrichments at baseline tend to be upregulated upon decitabine treatment, as opposed to genes with low H3K27me3 enrichments. This suggests pretreatment epigenetic patterns may dictate gene responses to decitabine therapy. Finally, our data indicate that decitabine may diminish epigenetic differences between two cell subpopulations by pushing all cells towards a more differentiated state. In conclusion, we have shown that leukemia initiating capacity is regulated not only by DNA methylation but also chromatin modifications. Decitabine treatment may decrease stemness features through complex interactions of epigenetic controls. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T02:50:35Z (GMT). No. of bitstreams: 1 ntu-106-R04447001-1.pdf: 4485881 bytes, checksum: 6cb9effa7ed32d82595a7d9fdf6ebb75 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 1. Introduction 1
1.1 Brief introduction of epigenetics 1 1.2 Acute myelogenous leukemia and leukemic stem cells 3 1.3 Epigenetic mechanisms in stem cell differentiation 3 1.4 5-Aza-2'-deoxycytidine (Decitabine) 4 1.5 Rationale for the study 5 1.6 Significance of the study 6 2. Materials and Methods 8 2.1 Cell culture of human leukemia cell line, Kasumi-1 8 2.2 Drug treatment 8 2.3 Gene expression microarrays 8 2.4 DNA methylation microarrays 9 2.5 Chromatin immunoprecipitation sequencing (ChIP-seq) 9 2.6 Data analysis on gene expression arrays 10 2.7 Gene ontology (GO) and Gene Set Enrichment Analysis (GSEA) 11 2.8 Data analysis on DNA methylation arrays 12 2.9 Expression quantitative trait methylations (eQTMs) in leukemia 12 2.10 Data analysis on ChIP-seq data 13 2.11 Software tools for data analyses 14 3. Results 15 3.1 Selection of eQTM probes in acute myelogenous leukemia 15 3.2 Transcriptomic analysis of CD34pos and CD34neg Kasumi-1 cell 15 3.3 Methylome analysis between CD34pos and CD34neg cells 16 3.4 Histone modification analysis between CD34pos and CD34neg cells 17 3.5 Transcriptomic analysis of Kasumi-1 cells after decitabine treatment 18 3.6 Methylome analysis of Kasumi-1 cell after decitabine treatment 19 3.7 histone modification analysis of Kasumi-1 cell after decitabine treatment 20 3.8 Other gene targets induced by decitabine 21 4. Discussion 22 4.1 Epigenetics behind stemness of CD34pos cells 22 4.2 Epigenetics behind decitabine induced transcrtipomics in Kasumi-1 cells 22 4.3 Decitabine’s effect on immunotherapy targets 24 5. Conclusion 26 6. References: 27 | |
dc.language.iso | en | |
dc.title | DNA去甲基化藥物於血癌細胞亞群的表觀遺傳效應整合分析 | zh_TW |
dc.title | Integrative analysis of epigenomic responses to DNA demethylating agents in leukemic cell subpopulations | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 周文堅,陳沛隆 | |
dc.subject.keyword | 表觀遺傳學,去甲基化藥物,急性骨髓性白血病, | zh_TW |
dc.subject.keyword | Epigenetics,DNA demethylating agents,Acute myeloid leukemia, | en |
dc.relation.page | 91 | |
dc.identifier.doi | 10.6342/NTU201703534 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2017-08-16 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 毒理學研究所 | zh_TW |
顯示於系所單位: | 毒理學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 4.38 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。